All In Biotech

Drug Trial Radar · NCT03860857

Biomarker Exploration in Aging, Cognition and Neurodegeneration

The BEACoN Study- Biomarker Exploration in Aging, Cognition and Neurodegeneration

Last checked: Nov 19, 2026Latest source record: Jan 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

May 1, 2018

Primary completion

Dec 22, 2026

Study completion Dec 22, 2027

Sponsor

Lead sponsor
University of California, IrvineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Aging (NIA)
First posted
Mar 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Health services research
FDA-regulated drug
Yes
Who can join
All sexes, from 60 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this research study is to understand the factors that underlie changes in thinking and memory with increasing age. The investigators will test the usefulness of MRI, PET, and cognitive testing in detecting subtle changes in the brain that precede cognitive decline. An addendum to this study includes additional PET scans to examine the relationship between tau protein in the brain and cognitive decline. Tau is a protein that is known to form tangles in the areas of the brain important for memory, and these tau tangles are a hallmark of Alzheimer's disease. This sub-study research aims to look at the tau accumulation in the brain using an investigational drug called MK-6240, which is a radio tracer that gets injected prior to a positron emission tomography (PET) scan.

Conditions

  • Alzheimer Disease
  • Cognitive Impairment
  • Cognitive Decline

Interventions

  • Amyloid PET scanRadiation

    Amyloid Positron Emission Tomography scan using radio tracer florbetapir-F18

  • Tau PET scan using MK-6240Drug

    Tau Positron Emission Tomography scan using radio tracer MK-6240

  • Neurocognitive testingBehavioral

    A battery of clinical neuropsychological assessments and computerized cognitive tasks will be used to test participants' memory and cognitive abilities.

  • MRIOther

    High-resolution structural, functional, and diffusion Magnetic Resonance Imaging scans will be collected during the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Clinical Dementia Rating - Sum of Box ScoreTime frame: Years 4 and 5 of the grant

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of California, Irvine

    Irvine, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.